Name: UMIN ID:
Unique ID issued by UMIN | UMIN000002738 |
---|---|
Receipt number | R000002521 |
Scientific Title | Cohort study evaluating efficacy of trastuzumab retreatment in recurrent breast cancer patients who previously received trastuzumab adjuvant therapy. |
Date of disclosure of the study information | 2009/11/11 |
Last modified on | 2019/09/05 13:47:15 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2009/11/10 14:13:31 | ||
2 | Update | 2009/11/11 14:18:24 | Recruitment status |
|
3 | Update | 2009/12/22 20:40:12 | Recruitment status |
|
4 | Update | 2010/02/08 18:54:57 | Email1 |
|
5 | Update | 2011/11/11 17:57:00 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
6 | Update | 2012/05/16 13:58:35 | Institutions |
|
7 | Update | 2012/11/11 14:37:18 | Recruitment status |
|
8 | Update | 2013/06/17 16:40:50 | Institute Organization |
|
9 | Update | 2013/06/17 16:41:26 | Acronym Acronym |
|
10 | Update | 2013/06/17 16:50:35 | Organization |
|
11 | Update | 2015/05/11 12:37:00 | Email |
|
12 | Update | 2015/05/11 12:38:09 | Date of closure to data entry Date trial data considered complete |
|
13 | Update | 2016/07/08 14:57:23 | Address Address TEL Name of primary person or sponsor Organization |
|
14 | Update | 2016/11/15 16:30:45 | Anticipated trial start date Date analysis concluded |
|
15 | Update | 2017/11/16 13:39:30 | Results |
|
16 | Update | 2018/08/13 15:15:32 | Recruitment status Publication of results URL related to results and publications Results |
|
17 | Update | 2018/08/23 17:35:04 | Public title |
|
18 | Update | 2019/09/05 13:14:34 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
19 | Update | 2019/09/05 13:47:15 | Recruitment status Date of IRB |